- Bluebird plans to separate its severe genetic disease & oncology businesses into differentiated and independent publicly traded companies. The company will retain focus on SGD and will launch its oncology business (“Oncology Newco”) as a new entity
- The spinoff is expected to result in two independent, publicly traded companies by the end of 2021
- The spinoff is designed to unlock value through improved operational execution, organizational focus, tailored capital allocation, and enhanced strategic optionality
Click here to read full press release/ article | Ref: Businesswire | Image: Fierce Pharma
The post Bluebird bio to Spin Off its Oncology Business into Independent Company first appeared on PharmaShots.